A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors - M19-345

AbbVie Deutschland GmbH & Co. KG0 sites290 target enrollmentDecember 18, 2023

ConditionsSolid Tumors, Locally Advanced or Metastatic Solid Tumors MedDRA version: 20.0Level: LLTClassification code: 10025648Term: Malignant mast cell tumors unspecified site extranodal and solid organ sites Class: 10029104 Therapeutic area: Diseases [C] - Neoplasms [C04]

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Solid Tumors, Locally Advanced or Metastatic Solid Tumors
Sponsor: AbbVie Deutschland GmbH & Co. KG
Enrollment: 290
Status: Recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

December 18, 2023

End Date

TBD

Last Updated

last year

Study Type

Interventional clinical trial of medicinal product

Sex

All

Investigators

Sponsor

AbbVie Deutschland GmbH & Co. KG

Eligibility Criteria

Inclusion Criteria

•For Dose Escalation only: Subjects with an advanced solid tumor who are considered refractory to or intolerant of all existing therapy(ies) known to provide a clinical benefit for their condition. Additionally, subjects who have been offered standard therapies and refused, or who are considered ineligible for standard therapies, may be eligible for this study on a case\-by\-case basis, after discussion with and agreement from the sponsor., Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1\., For Dose Expansion only: Subjects must have measurable disease per RECIST1\.1, For Dose Expansion only: All subjects with MSS\-CRC, HCC, or pancreatic adenocarcinoma must not have had prior treatment with a PD\-1/PDL\-1 antagonist in any line of therapy, Subject has adequate bone marrow, renal, hepatic, and coagulation function., For Dose Escalation only: Subjects with pancreatic adenocarcinoma, urothelial cancer, Hepatocellular carcinoma (HCC), or Head and neck squamous cell carcinoma (HNSCC) who are being considered for the dose escalation cohorts must also meet the histology specific eligibility criteria described below for dose expansion., For Dose Expansion only subjects must meet criteria specific to the type of cancer: Pancreatic adenocarcinoma and have disease progression during or after 1 systemic therapy (including gemcitabine monotherapy or in combination with other agents, FOLFIRINOX \[or another regimen including both 5\-fluorouracil and oxaliplatin], capecitabine monotherapy or in combination with other agents) administered in the adjuvant, locally advanced, or metastatic setting. Progression on more than 1 prior systemic therapy is not allowed in this cohort. If the therapy was used in an adjuvant setting, disease progression must have occurred within 6 months of completing adjuvant therapy., For Dose Expansion only subjects must meet criteria specific to the type of cancer: Urothelial cancer of the bladder and urinary tract and must have progressed following treatment with a platinum\-based regimen (administered in any line of therapy) and a programmed death 1/programmed death ligand 1 (PD1/PDL1\) antagonist administered in the recurrent or metastatic setting (progression following a PD1/PDL1 antagonist is defined as unequivocal progression on or within 3 months of the last dose of anti\-PD1 or anti\-PDL1 therapy)., For Dose Expansion only subjects must meet criteria specific to the type of cancer: HCC and must have disease progression during or after 1 prior line of systemic therapy. Progression on more than 1 prior systemic therapy is not allowed in this cohort., For Dose Expansion only subjects must meet criteria specific to the type of cancer: HNSCC (arising from the oral cavity, oropharynx, hypopharynx, or larynx) and must have progressed following treatment with platinum\-based regimen (administered in any line of therapy) and a PD1/PDL1 antagonist administered in the recurrent or metastatic setting (progression following a PD1/PDL1 antagonist is defined as unequivocal progression on or within 3 months of the last dose of anti\-PD1 or antiPDL1 therapy)., For Dose Expansion only subjects must meet criteria specific to the type of cancer: MSS\-CRC subjects with microsatellite stable or mismatch repair proficient colorectal adenocarcinoma (as determined by PCR/NGS or IHC, respectively) who have received prior fluorouracil\-based combination chemotherapy regimens including oxaliplatin and irinotecan (with or with

Exclusion Criteria

•Has received anticancer therapy including chemotherapy, immunotherapy, radiation therapy, biologic, herbal therapy, or any investigational therapy within a period of 5 half\-lives or 28 days (whichever is shorter), prior to the first dose of the study drug., Subject has unresolved AEs \> Grade 1 from prior anticancer therapy except for alopecia., Has a history of primary immunodeficiency, bone marrow transplantation, solid organ transplantation, or previous clinical diagnosis of tuberculosis., Has a known uncontrolled metastases to the central nervous system (with certain exceptions)., Current or prior use of immunosuppressive medication within 14 days prior to the first dose of the study drug.